BREAKING NEWS

President leans toward dumping insurer subsidies
Snail-paced regulators get up to Silicon Valley speed
Analyst gives treatment 50/50 chance of coming to market
The AGs hope to prevent cuts in subsidy payments to insurance companies
Finding could lead to the first broadly effective ebolavirus therapies and vaccines
Approval marks the fifth type of cancer for which the drug is indicated
Researchers analyzed data from large studies that included more than 800,000 men
Use of in vitro assay data could potentially apply to other medications

P&T TV

Dr. David B. Nash Sees Problems Ahead With Pending GOP Health Care Overhaul

Potential harm stemming from repeal of the Patient Protection and Affordable Care Act worries Dr. David B. Nash, Dean of the Jefferson College of Population Health. In an interview with P&T Editor Steve McIver, Dr. Nash also discusses the future of Medicare, drug pricing, and other key issues facing the health care system.

April 2017 interview

P&T May 2017
Table of Contents

Features

The next iterations of the Generic Drug User Fee Act and the Biosimilar User Fee Act are meant to encourage new generic and biosimilar products, but higher fees and budget reductions may threaten progress.
The authors summarize newly available HCV treatment regimens, their indications, studies supporting their efficacy and safety, and special considerations for each regimen, such as patient comorbidities.
Health Care & Law
The pharmacy benefit management (PBM) industry has recently fallen into the crosshairs of government investigations about the high cost of pharmaceuticals. The authors focus on the PBM-based P&T and formulary practices under scrutiny.
The new USP standard for handling hazardous drugs (HDs) will require millions of dollars in capital outlays for facility and equipment upgrades and also requires in-depth assessments of each HD that facilities handle, significant workflow and work practice changes, and thorough staff training.
Meeting Highlights
We report on selected research presented at the ACC 66th Annual Scientific Session and Expo, including sessions on proprotein convertase subtilisin/kexin type 9 inhibitors, anti-Xa anticoagulants, and a direct thrombin inhibitor.

Departments

Medication Errors
Speaking “off the cuff” is a prescription for disaster in health care
Prescription: Washington
Drug companies worry about new FDA “totality of evidence” standard
Approvals, new indications, regulatory activities, and more
Brodalumab (Siliq) for moderate-to-severe plaque psoriasis in adults; telotristat ethyl (Xermelo) for carcinoid syndrome diarrhea in combination with somatostatin analogue therapy in adults; and desmopressin acetate (Noctiva) for adults with nocturnal polyuria
Letter to the Editor
Drug Forecast
Otiprio: an FDA-approved ciprofloxacin suspension gel for pediatric otitis media